References
1. Yousefifard M, Zali A, Mohamed Ali K, et al. Antiviral therapy in management of COVID-19: a systematic review on current evidence.Arch Acad Emerg Med . 2020;8(1):e45. http://www.ncbi.nlm.nih.gov/pubmed/32309809.
2. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. Jama . 2020. doi:10.1001/jama.2020.6775
3. Bessière F, Roccia H, Delinière A, et al. Assessment of QT Intervals in a Case Series of Patients with Coronavirus Disease 2019 (COVID-19) Infection Treated with Hydroxychloroquine Alone or in Combination with Azithromycin in an Intensive Care Unit. JAMA Cardiol . 2020. doi:10.1001/jamacardio.2020.1787
4. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med . 2020. doi:10.1056/nejmoa2001282
5. Francis J, Barnes KI, Workman L, et al. An individual participant data population pharmacokinetic meta-analysis of drug-drug interactions between lumefantrine and commonly used antiretroviral treatment.Antimicrob Agents Chemother . 2020;64(5). doi:10.1128/AAC.02394-19
6. Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and InducersNo Title. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table3-1. Published 2020. Accessed June 15, 2020.
7. Hughes CA, Tseng A, Cooper R. Managing drug interactions in HIV-infected adults with comorbid illness. Cmaj . 2015;187(1):36-43. doi:10.1503/cmaj.131626
8. Liu X, Ma Q, Yan Z, et al. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.Pharmacotherapy . 2017;37(9):1073-1080. doi:10.1002/phar.1988
9. FDA. Highlights of prescribing information of lopinavir/ritonavir. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021226s038lbl.pdf. Published 2020. Accessed June 2, 2020.
10. University of Liverpool. Detailed recommendations for interactions with experimental COVID-19 antiviral therapies. https://www.covid19-druginteractions.org/prescribing-resources. Published 2020. Accessed June 4, 2020.
11. Nanji KC, Seger DL, Slight SP, et al. Medication-related clinical decision support alert overrides in inpatients. J Am Med Inform Assoc . 2018;25(5):476-481. doi:10.1093/jamia/ocx115
12. Zenziper Straichman Y, Kurnik D, Matok I, et al. Prescriber response to computerized drug alerts for electronic prescriptions among hospitalized patients. Int J Med Inform . 2017;107:70-75. doi:10.1016/j.ijmedinf.2017.08.008
13. McEvoy DS, Sittig DF, Hickman TT, et al. Variation in high-priority drug-drug interaction alerts across institutions and electronic health records. J Am Med Informatics Assoc . 2017;24(2):331-338. doi:10.1093/jamia/ocw114